Home Cart 0 Sign in  
X

[ CAS No. 18595-14-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 18595-14-7
Chemical Structure| 18595-14-7
Chemical Structure| 18595-14-7
Structure of 18595-14-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 18595-14-7 ]

Related Doc. of [ 18595-14-7 ]

Alternatived Products of [ 18595-14-7 ]

Product Details of [ 18595-14-7 ]

CAS No. :18595-14-7 MDL No. :MFCD00102230
Formula : C9H11NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZHIPSMIKSRYZFV-UHFFFAOYSA-N
M.W : 165.19 Pubchem ID :2736799
Synonyms :

Calculated chemistry of [ 18595-14-7 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 47.09
TPSA : 52.32 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.1 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.9
Log Po/w (XLOGP3) : 1.7
Log Po/w (WLOGP) : 1.37
Log Po/w (MLOGP) : 1.64
Log Po/w (SILICOS-IT) : 1.44
Consensus Log Po/w : 1.61

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.17
Solubility : 1.11 mg/ml ; 0.00671 mol/l
Class : Soluble
Log S (Ali) : -2.41
Solubility : 0.637 mg/ml ; 0.00385 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.49
Solubility : 0.531 mg/ml ; 0.00321 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.31

Safety of [ 18595-14-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 18595-14-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 18595-14-7 ]
  • Downstream synthetic route of [ 18595-14-7 ]

[ 18595-14-7 ] Synthesis Path-Upstream   1~28

  • 1
  • [ 543-87-3 ]
  • [ 18595-14-7 ]
  • [ 144-55-8 ]
  • [ 61700-61-6 ]
Reference: [1] Patent: EP1256574, 2002, A1,
  • 2
  • [ 18595-14-7 ]
  • [ 61700-61-6 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 1, p. 350 - 364
[2] Chemical Communications, 2012, vol. 48, # 94, p. 11558 - 11560
[3] Patent: US2012/277224, 2012, A1,
[4] Patent: WO2013/97773, 2013, A1,
  • 3
  • [ 18595-14-7 ]
  • [ 25978-68-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
  • 4
  • [ 18595-14-7 ]
  • [ 3095-48-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 14, p. 3033 - 3044
  • 5
  • [ 75-18-3 ]
  • [ 18595-14-7 ]
  • [ 3095-48-5 ]
Reference: [1] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2010, vol. 75, # 1, p. 320 - 324
  • 6
  • [ 18595-14-7 ]
  • [ 5471-81-8 ]
Reference: [1] Advanced Synthesis and Catalysis, 2010, vol. 352, # 9, p. 1451 - 1454
[2] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
  • 7
  • [ 24078-21-5 ]
  • [ 18595-14-7 ]
YieldReaction ConditionsOperation in experiment
96% With 5%-palladium/activated carbon; hydrogen In ethanolFlow reactor General procedure: Before each run, the system (see Fig.4) was allowed to equilibrate by pumping solvent through for 30min with the Tube-in-Tube device at 16bar of hydrogen. An omnifit cartridge (20.0mm OD, 15.0mm ID) containing 1g of Pd-C catalyst was used. To avoid an overpressure of the system in the event of blockage, the upper pressure cut-off limit on the Knauer pump was set to 25bar. With the injection loop disconnected from the flow line, the loop was opened and filled manually (using a syringe) with 3.6mL of a 0.076M solution of starting material in ethanol (excess starting material solution exiting the loop was recovered for reuse). The injection loop was then closed off and switched into the flow stream. The outlet from the system (downstream of the back-pressure regulator) was collected for 120min. The solvent was removed under reduced pressure (using a rotary evaporator followed by a 2-stage rotary vane pump) to afford the product.
90%
Stage #1: With hydrogenchloride In water; ethyl acetate
Stage #2: With zinc In water; ethyl acetate at 0 - 20℃; for 15.33 h;
Stage #3: With sodium hydrogencarbonate In water; ethyl acetate
Methyl 3-methyl-4-nitrobenzoate (23 g, 117.84 mmol) was dissolved in ethyl acetate (400 mL) and cond HCl (58 mL). Then the solution was cooled to 0 °C and Zn powder (46.2 g, 707 mmol) was added in portions over 20 min with stirring. The mixture was allowed to warm up to room temperature and stirring was continued for 15 h. The reaction mixture was passed through a bed of Celite and washed with ethyl acetate (100 mL). The filtrate was washed with satd NaHCO3 solution (4 .x. 100 mL), water (3 .x. 100 mL) and brine (2 .x. 100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to dryness to obtain the amino compound 5 (17.4 g, 90.0percent) as a colorless solid. mp 111-113 °C; 1H NMR (300 MHz, CDCl3) δ 2.18 (s, 3H), 3.85 (s, 3H), 4.02 (s, br, 2H), 6.65 (d, J = 8.1 Hz, 1H), 7.76-7.72 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 17.2, 51.7, 113.8, 119.5, 121.1, 129.4, 132.3, 149.5, 167.6; MS (ES) m/z 166 (M+1).
90% With palladium on activated charcoal; hydrogen In methanol at 20℃; To a solution of methyl 3-methyl-4-nitrobenzoate (50 g, 256.2mmol) in methanol (1.5L) was added palladium on carbon (2.5 g). Then H2 (g) was introduced and the reaction was stirred overnight at room temperature. The solids were filtered off and the resulting solution was concentrated in vacuo to afford methyl 4- amino- 3- methylbenzoate as a light yellow solid (38 g, 90percent). LCMS (ES, m/z): [M+H]+ 166.1
80% With hydrogen In methanol at 20℃; Step 2.
Methyl 4-amino-3-methylbenzoate
To a solution of methyl 3-methyl-4-nitrobenzoate (31 g, 158.83 mmol) in methanol (1000 mL) was added palladium on carbon (2 g), and the reaction was stirred overnight at room temperature under an atmosphere of H2(g).
Then the solids were filtered out and filtrate was concentrated under vacuum to afford methyl 4-amino-3-methylbenzoate as a white solid (21 g, 80percent).
LC/MS (ES, m/z): [M+H]+ 166.0
1H-NMR (300 MHz, CD3Cl) δ 7.74-7.77 (m, 2H), 6.52 (d, J=8.1 Hz, 1H), 4.09-4.11 (m, 2H), 3.87 (s, 3H), 2.20 (s, 3H)
62% With iron; ammonium chloride In methanol; water for 4 h; Reflux To a stirred solution of methyl 3-methyl-4-nitrobenzoate (50 g, 1.0 eq) in 1 L MeOH were added at rt a solution of NH4CI (137 g, 10 eq) in 60 mL H20 and Fe power (96 g, 7 eq), and the resulting mixture is heated at reflux for 4 h. The reaction mixture was allowed to cool to rt, filtered, and water was added. The mixture was extracted with EtOAc. The extract was dried, washed with water, and concentrated to give the desired product directly as a white solid (26 g, 62percent).

Reference: [1] Tetrahedron, 2018, vol. 74, # 47, p. 6795 - 6803
[2] Journal of Heterocyclic Chemistry, 2003, vol. 40, # 6, p. 1107 - 1112
[3] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 14, p. 4582 - 4589
[4] Patent: WO2014/66795, 2014, A1, . Location in patent: Paragraph 0175
[5] Zeitschrift fur Anorganische und Allgemeine Chemie, 2014, vol. 640, # 1, p. 159 - 167
[6] Chemical Communications, 2012, vol. 48, # 94, p. 11558 - 11560
[7] Patent: US2012/277224, 2012, A1, . Location in patent: Page/Page column 34
[8] Asian Journal of Chemistry, 2014, vol. 26, # 7, p. 1921 - 1930
[9] Patent: WO2013/97773, 2013, A1, . Location in patent: Paragraph 0258
[10] Chemische Berichte, 1895, vol. 28, p. 597
[11] European Journal of Medicinal Chemistry, 1983, vol. 18, # 4, p. 307 - 314
[12] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
[13] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 81 - 84
  • 8
  • [ 3113-71-1 ]
  • [ 18595-14-7 ]
YieldReaction ConditionsOperation in experiment
99% With H2 In methanol (a)
Methyl 4-amino-3-methylbenzoate. To a solution of 3-methyl-4-nitrobenzoic acid (6.50 g, 33.3 mmol) in 100 mL of MeOH was added 700 mg of 5percent Pd/C.
The mixture was hydrogenated at 48 psi H2 for 24 hours, the catalyst was removed by suction filtration, and the filtrate was concentrated under reduced pressure.
The title compound was obtained as a white solid (99percent).
1H NMR (CDCl3) δ: 2.19 (s, 3H), 3.85 (s, 3H), 4.20 (br s, 2H), 6.65 (d, 2H, J = 8.1Hz), 7.72 (d, 2H, J = 8.1Hz), 7.76 (s, 1H). Anal. (C9H11NO2) C, H, N.
Reference: [1] Patent: EP1109560, 2003, B1,
[2] Journal of Heterocyclic Chemistry, 2003, vol. 40, # 6, p. 1107 - 1112
[3] Chemische Berichte, 1895, vol. 28, p. 597
[4] Chemical Communications, 2012, vol. 48, # 94, p. 11558 - 11560
[5] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 81 - 84
[6] Patent: US2012/277224, 2012, A1,
[7] Zeitschrift fur Anorganische und Allgemeine Chemie, 2014, vol. 640, # 1, p. 159 - 167
[8] Patent: WO2014/66795, 2014, A1,
[9] Asian Journal of Chemistry, 2014, vol. 26, # 7, p. 1921 - 1930
  • 9
  • [ 67-56-1 ]
  • [ 2486-70-6 ]
  • [ 18595-14-7 ]
YieldReaction ConditionsOperation in experiment
95% With thionyl chloride In dichloromethane at 80℃; for 3 h; Step 1.
Methyl 4-amino-3-methylbenzoate
A solution of 4-amino-3-methylbenzoic acid (60 g, 396.92 mmol) and SOCl2 (141.9 g, 1.19 mol) in methanol (700 mL) was stirred 3 hours at 80° C.
The resulting solution was concentrated in vacuo to afford a residue, which was dissolved in dichloromethane (500 mL) and washed with saturated aqueous sodium bicarbonate, dried over anhydrous magnesium sulfate and concentrated in vacuo to afford methyl 4-amino-3-methylbenzoate (62 g, 95percent) as a pink solid.
LC/MS (ES, m/z): [M+H]+ 152.1
1H-NMR (300 MHz, CDCl3) δ 7.78 (d, J=0.6 Hz, 1H), 7.74 (d, J=2.1 Hz, 1H), 6.65 (d, J=8.1 Hz, 1H), 4.11 (s, 2H), 3.87 (s, 3H), 2.20 (s, 3H)
95% at 20℃; for 12 h; 4-Amino-3-methylbenzoic acid (20 mmol) and 30 ml MeOH were placed in a flask, and SOCl2 (24 mmol) were added dropwise at -5 °C.
The reaction kept for 12 h at room temperature.
The solvent was evaporated and the residue was basified with NaHCO3 to PH 7 or 8, extracted with ethyl acetate (EA).
The dried organic phase was concentrated to get the compound 4. White solid, yield 95percent, mp 119-120 °C; 1H NMR (400 Hz, CDCl3) δ (ppm): 2.07 (s, 3H, Ar-CH3), 3.73 (s, 3H, OCH3), 5.74 (s, 2H, NH2), 6.60 (d, 1H, JH = 8.0 Hz, Ar-H), 7.52 (dd, 1H, J12 = 2.0 Hz, J13 = 8.4 Hz, J34 = 2.0 Hz, Ar-H), 7.55 (s, 1H, Ar-H).
92% at 90℃; for 10 h; To a solution of 4-amino-3-methylbenzoic acid (80 g, 529.23 mmol) in methanol (1000 mL) was added thionyl chloride (250 g) with stirring for 10 h at 90°C. The resulting mixture was concentrated under vacuum. The resulting mixture was diluted with H20 (200 mL), extracted with dichloromethane (3 x 150 mL) and the organic layers combined and dried over anhydrous sodium sulfate. The solids were filtered out to give the filtered, which was concentrated under vacuum to afford methyl 4-amino-3-methylbenzoate as a light yellow solid (80 g, 92percent). LCMS (ES, m/z): [M+H]+ 166.0 *H NMR (300 MHz, DMSO) δ 8.25 (brs, 2H), 7.60 (s, 1H), 7.59 (s, 1H), 6.86 (d, J = 8.40Hz, 1H), 3.76 (s, 3H), 2.16 (s, 2H)
Reference: [1] Advanced Synthesis and Catalysis, 2010, vol. 352, # 9, p. 1451 - 1454
[2] Patent: US2012/277224, 2012, A1, . Location in patent: Page/Page column 39
[3] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 22, p. 6366 - 6379
[4] Patent: WO2014/66795, 2014, A1, . Location in patent: Paragraph 0175
[5] Journal of Organic Chemistry, 1996, vol. 61, # 17, p. 5804 - 5812
[6] Patent: EP1568688, 2005, A1, . Location in patent: Page/Page column 30
[7] Patent: US2004/132779, 2004, A1, . Location in patent: Page/Page column 17
[8] Journal of Photochemistry and Photobiology A: Chemistry, 2010, vol. 213, # 2-3, p. 164 - 170
  • 10
  • [ 186581-53-3 ]
  • [ 2486-70-6 ]
  • [ 18595-14-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2001, vol. 44, # 25, p. 4416 - 4430
  • 11
  • [ 619-50-1 ]
  • [ 676-58-4 ]
  • [ 18358-63-9 ]
  • [ 18595-14-7 ]
Reference: [1] Tetrahedron, 1987, vol. 43, # 18, p. 4221 - 4226
  • 12
  • [ 18595-14-7 ]
  • [ 42113-13-3 ]
YieldReaction ConditionsOperation in experiment
42%
Stage #1: With sulfuric acid In water at 0℃;
Stage #2: With sodium nitrite In water at 0℃; for 0.0833333 h;
4-Amino-3-methyl-benzoic acid methyl ester (5.25g, 32.0mmol) was treated with a 35percent solution of sulphuric acid (50ml) and the mixture was stirred and heated un;til dissolution then cooled to 0°C. Sodium nitrite (2.82g, 41.6mmol) in water (50ml) was added dropwise and the mixture was stirred for 5min at 0°C. Urea was added to destroy the excess nitrite. Copper nitrate (121g, 320mmol) in water (11) was added then copper ox;ide (4.25g, 32.0mmol). The mixture was warmed up to room temperature over 30 min and extracted with EtOAc (x 3). The organics were combined, washed with brine, dried and concentrated in vacuo. The residue was puri;fied by flash chromatography on silica gel (eluant; 30percent EtOAc:70percent hexane) to yield the title compound (2.2g, 42percent) .
Reference: [1] Patent: WO2006/21213, 2006, A2, . Location in patent: Page/Page column 55
  • 13
  • [ 18595-14-7 ]
  • [ 78881-21-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 22, p. 6366 - 6379
  • 14
  • [ 18595-14-7 ]
  • [ 148547-19-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
  • 15
  • [ 18595-14-7 ]
  • [ 152628-03-0 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2003, vol. 40, # 6, p. 1107 - 1112
[2] Journal of Medicinal Chemistry, 1993, vol. 36, # 25, p. 4040 - 4051
[3] European Journal of Medicinal Chemistry, 2016, vol. 115, p. 161 - 178
  • 16
  • [ 18595-14-7 ]
  • [ 141-75-3 ]
  • [ 152628-03-0 ]
Reference: [1] RSC Advances, 2017, vol. 7, # 42, p. 26401 - 26410
  • 17
  • [ 18595-14-7 ]
  • [ 141-75-3 ]
  • [ 301533-59-5 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2003, vol. 40, # 6, p. 1107 - 1112
[2] Journal of Medicinal Chemistry, 1993, vol. 36, # 25, p. 4040 - 4051
[3] European Journal of Medicinal Chemistry, 2016, vol. 115, p. 161 - 178
  • 18
  • [ 18595-14-7 ]
  • [ 152628-02-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1993, vol. 36, # 25, p. 4040 - 4051
[2] European Journal of Medicinal Chemistry, 2016, vol. 115, p. 161 - 178
  • 19
  • [ 18595-14-7 ]
  • [ 144701-48-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1993, vol. 36, # 25, p. 4040 - 4051
  • 20
  • [ 18595-14-7 ]
  • [ 180624-25-3 ]
Reference: [1] Journal of Organic Chemistry, 1996, vol. 61, # 17, p. 5804 - 5812
  • 21
  • [ 18595-14-7 ]
  • [ 473416-12-5 ]
YieldReaction ConditionsOperation in experiment
62%
Stage #1: With hydrogenchloride; ammonium tetrafluoroborate; sodium nitrite In water for 0.583333 h;
Stage #2: With 18-crown-6 ether; potassium acetate In chloroform; water at 20℃; for 2 h;
Step 3.
Methyl 1H-indazole-5-carboxylate
To a solution of methyl 4-amino-3-methylbenzoate (21 g, 133.18 mmol) in HCl (15 mL) and water (85 mL) was added NH4BF4 (20 g) and NaNO2 (10 g, 144.93).
The mixture was stirred for 35 minutes, and the solids were collected by filtration and added in one portion to a stirred mixture of KOAc (16 g, 163.03 mmol) and 18-crown-6 (500 mg, 1.89 mmol) in CHCl3 (170 mL).
After stirring for 2 hours at room temperature, the mixture was washed with water (100 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure to afford a residue, which was purified by a silica gel column with 30percent ethyl acetate in petroleum ether to afford methyl 1H-indazole-5-carboxylate as a white solid (14.5 g, 62percent).
LC/MS (ES, m/z): [M+H]+ 177.0
1H-NMR (300 MHz, CDCl3) δ 8.58-8.59 (m, 1H), 8.23 (s, 1H), 8.09-8.13 (m, 1H), 7.54 (d, J=9.0 Hz, 1H), 3.98 (s, 3H)
55%
Stage #1: With tetrafluoroboric acid; sodium nitrite In water at 0 - 20℃; for 4 h;
Stage #2: With 18-crown-6 ether; potassium acetate In chloroform; water at 0 - 20℃; for 3 h; Inert atmosphere
NaN02 (20 g, 0.29 mol) was added portion wise to a solution of methyl 4-amino-3- methylbenzoate (38 g, 0.23 mol) in aqueous HBF4 (48 wt, 200 mL) at 0°C. The reaction was allowed to stir for 4 h at room temperature. The solids were collected by filtration and washed with 3x200 mL of ether. The solids were dried in an oven under reduced pressure. Under an inert atmosphere of nitrogen, was placed CH3COOK (45 g, 0.46mol), 18-crown-6 (3 g, 0.012mol), and chloroform (200 mL). This was followed by the portion wise addition of the dried solid at 0°C. The reaction was stirred for 3 h at room temperature. Then 1 L of H20 was added and the resulting solution was extracted with 5x100 mL of DCM. The organic layers were dried over anhydrous sodium sulfate and the filtrate was concentrated in vacuo to afford a residue which was purified by silica gel column chromatography with 1percent methanol in CH2Cl2 to afford of methyl lH-indazole-5-carboxylate as a yellow solid (22 g, 55percent). LCMS (ES, m/z): [M+H]+ 177.1 *H NMR (300 MHz, DMSO) δ 13.41 (s, 1H), 8.50 (s, 1H), 8.26 (s, 1H), 7.94 - 7.90 (dd, / = 1.50, 8.70 Hz, 1H), 7.64 (d, / = 8.70 Hz, 1H), 3.90 (s, 3H)
30% With acetic acid; sodium nitrite In water at 20℃; for 5 h; A solution of sodium nitrite (836 mg, 59.1 mmol) in water (2 ml) was added to a solution of methyl 4-amino-3-methylbenzoate (2.00 g, 12.1 mmol) in acetic acid (80 ml) at room temperature and stirred at room temperature for 5 hours. The reaction solution was concentrated and the resulting residue was diluted with chloroform and washed with a 5percent aqueous sodium hydrogencarbonate solution and then a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and distilled under reduced pressure to remove the solvent, and the resulting residue was purified by a silica gel column chromatography (eluent: hexane/ethyl acetate = 3/1) to obtain methyl 1H-indazole-5-carboxylate (645 mg, 30percent).1H-NMR (DMSO-d6) δ; 3.86 (3H, s), 7.61 (1H, d, J=8.8Hz), 7.91 (1H, d, J=8.8Hz), 8.25 (1H, s), 8.48 (1H, brs), 13.41 (1H, brs).
Reference: [1] Patent: US2012/277224, 2012, A1, . Location in patent: Page/Page column 34
[2] Patent: WO2014/66795, 2014, A1, . Location in patent: Paragraph 0175
[3] Patent: EP1403255, 2004, A1, . Location in patent: Page 43-44
[4] Patent: WO2013/97773, 2013, A1,
[5] Asian Journal of Chemistry, 2014, vol. 26, # 7, p. 1921 - 1930
[6] Patent: WO2014/129796, 2014, A1,
[7] Patent: WO2014/143666, 2014, A1, . Location in patent: Paragraph 00190
  • 22
  • [ 18595-14-7 ]
  • [ 108-24-7 ]
  • [ 473416-12-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 4, p. 1556 - 1564
  • 23
  • [ 18595-14-7 ]
  • [ 91367-05-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
  • 24
  • [ 18595-14-7 ]
  • [ 180636-50-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 15, p. 4416 - 4420
  • 25
  • [ 18595-14-7 ]
  • [ 1092351-82-0 ]
Reference: [1] Patent: WO2014/66795, 2014, A1,
  • 26
  • [ 18595-14-7 ]
  • [ 108-24-7 ]
  • [ 239075-26-4 ]
YieldReaction ConditionsOperation in experiment
1.2 g
Stage #1: at 0 - 20℃; for 1 h;
Stage #2: With potassium acetate; isopentyl nitrite In chloroform at 70℃; for 18 h;
4-Amino-3-methyl-benzoic acid methyl ester (2.0 g, 12.03 mmol) was dissolved in chloroform (25 mL) and then acetic anhydride (2.12 g, 30.07 mmol) was slowly added dropwise thereto at 0. The mixture was stirred for 1 hour at room temperature, and potassium acetate (250 mg, 3.61 mmol) and isoamyl nitrite (2.23 mL, 24.06 mmol) were added thereto. The mixture was stirred under reflux for 18 hours at 70 and added with excess dichloromethane. The mixture was washed with saturated sodium hydrogen carbonate aqueous solution, dried with anhydrous magnesium sulfate and filtered. The filtrate was distilled under reduced pressure. The residue was separated by column chromatography to obtain the intermediate acetyl indazole (1.2 g, 5.50 mmol).
Reference: [1] Chemical Communications, 2012, vol. 48, # 94, p. 11558 - 11560
[2] Patent: WO2014/129796, 2014, A1, . Location in patent: Paragraph 1225-1227
  • 27
  • [ 18595-14-7 ]
  • [ 900019-52-5 ]
YieldReaction ConditionsOperation in experiment
83% With N-Bromosuccinimide In dichloromethane at 20℃; for 3 h; A mixture of compound 1 (429 mg, 0.0026 mol) and NBS (0.7 g, 0.0039 mol) in DCM was stirred at r.t. for 3 h. The mixture was concentrated to a residue, which was purified by Prep-TLC to obtain compound 2 (522 mg, 83percent) as a light yellow solid
Reference: [1] Patent: US2014/128391, 2014, A1, . Location in patent: Paragraph 0599; 0600; 0601
  • 28
  • [ 18595-14-7 ]
  • [ 1427460-96-5 ]
Reference: [1] Patent: US2014/128391, 2014, A1,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 18595-14-7 ]

Telmisartan Related Intermediates

Chemical Structure| 152628-02-9

[ 152628-02-9 ]

1,7'-Dimethyl-2'-propyl-1H,1'H-2,5'-bibenzo[d]imidazole

Chemical Structure| 25148-68-9

[ 25148-68-9 ]

N-Methyl-1,2-benzenediamine dihydrochloride

Chemical Structure| 114772-53-1

[ 114772-53-1 ]

4'-Methyl-[1,1'-biphenyl]-2-carbonitrile

Chemical Structure| 301533-59-5

[ 301533-59-5 ]

Methyl 4-butyramido-3-methylbenzoate

Chemical Structure| 73183-34-3

[ 73183-34-3 ]

4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi(1,3,2-dioxaborolane)

Related Functional Groups of
[ 18595-14-7 ]

Aryls

Chemical Structure| 18595-18-1

[ 18595-18-1 ]

Methyl 3-amino-4-methylbenzoate

Similarity: 0.98

Chemical Structure| 24812-89-3

[ 24812-89-3 ]

Methyl 3-amino-2,4-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 3095-48-5

[ 3095-48-5 ]

Methyl 4-amino-3,5-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 41684-07-5

[ 41684-07-5 ]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

[ 63746-12-3 ]

Dimethyl 4-aminoisophthalate

Similarity: 0.96

Esters

Chemical Structure| 18595-18-1

[ 18595-18-1 ]

Methyl 3-amino-4-methylbenzoate

Similarity: 0.98

Chemical Structure| 24812-89-3

[ 24812-89-3 ]

Methyl 3-amino-2,4-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 3095-48-5

[ 3095-48-5 ]

Methyl 4-amino-3,5-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 41684-07-5

[ 41684-07-5 ]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

[ 63746-12-3 ]

Dimethyl 4-aminoisophthalate

Similarity: 0.96

Amines

Chemical Structure| 18595-18-1

[ 18595-18-1 ]

Methyl 3-amino-4-methylbenzoate

Similarity: 0.98

Chemical Structure| 24812-89-3

[ 24812-89-3 ]

Methyl 3-amino-2,4-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 3095-48-5

[ 3095-48-5 ]

Methyl 4-amino-3,5-dimethylbenzoate

Similarity: 0.98

Chemical Structure| 41684-07-5

[ 41684-07-5 ]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

[ 63746-12-3 ]

Dimethyl 4-aminoisophthalate

Similarity: 0.96